HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical and virological monitoring during treatment with intrathecal cytarabine in patients with AIDS-associated progressive multifocal leukoencephalopathy.

Abstract
We describe the clinical and virological outcome of human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy (PML) treated with cytarabine. Twenty-seven patients received intrathecal cytarabine, 5 received concomitant intravenous cytarabine, and 20 received concomitant antiretroviral therapy. The median baseline CD4+ cell count was 28/mm3. After 4 weeks, 4 (19%) of 21 evaluable patients had stable disease, whereas the others progressed. The median survival from diagnosis and from onset was 66 and 128 days, respectively. Patients with Karnofsky scores of >50 and those previously taking antiretroviral medications had a higher probability of survival 3 months after diagnosis (P = .003 and P = .05, respectively). Overall, after 4 weeks, median JC virus load in CSF increased by 0.7 log10 copies/mL from baseline (P = NS). The mean JC virus load at 4 weeks was lower in patients with stable disease than in progressors (3.47 vs. 4.47 log10 copies/mL; P = .027). JC virus became undetectable in the only patient who had a long-term stable condition. The concentration of JC virus in CSF showed a correlation with clinical outcome.
AuthorsA De Luca, M L Giancola, A Cingolani, A Ammassari, L Gillini, R Murri, A Antinori
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 28 Issue 3 Pg. 624-8 (Mar 1999) ISSN: 1058-4838 [Print] United States
PMID10194089 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-HIV Agents
  • Antiviral Agents
  • DNA, Viral
  • Cytarabine
Topics
  • AIDS-Related Opportunistic Infections (drug therapy, mortality, virology)
  • Adult
  • Anti-HIV Agents (therapeutic use)
  • Antiviral Agents (administration & dosage, therapeutic use)
  • Cytarabine (administration & dosage, therapeutic use)
  • DNA, Viral (cerebrospinal fluid)
  • Drug Therapy, Combination
  • Female
  • Humans
  • Injections, Spinal
  • JC Virus (isolation & purification)
  • Leukoencephalopathy, Progressive Multifocal (drug therapy, mortality, virology)
  • Male
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: